Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

Keyphrases

• United States 100%
• Immunosuppression 100%
• Post-transplant Lymphoproliferative Disorder 100%
• Renal Transplantation 100%
• Adjusted Hazard Ratio 80%
• Mycophenolate 30%
• Low Risk 20%
• OKT3 20%
• Pretransplant Malignancy 20%
• Risk Factors 10%
• Receptor Antagonist 10%
• Young Age 10%
• Induction Therapy 10%
• Lymphoma 10%
• Non-Hodgkin Lymphoma 10%
• Old Age 10%
• Cyclosporine 10%
• Prognostic Factors 10%
• Sirolimus 10%
• Kidney Transplant Recipients 10%
• Age-adjusted 10%
• Patient History 10%
• Mortality Factors 10%
• Tacrolimus 10%
• Poor Survival 10%
• United States Renal Data System (USRDS) 10%
• Antimetabolites 10%
• Incidence Risk 10%
• HLA Matching 10%
• Medicaid Patients 10%

Medicine and Dentistry

• Immunosuppressive Treatment 100%
• Posttransplant Lymphoproliferative Disease 100%
• Kidney Transplantation 100%
• Hazard Ratio 80%
• Mycophenolic Acid 30%
• Cancer 20%
• Azathioprine 20%
• Receptor 10%
• Medicare 10%
• Non-Hodgkin Lymphoma 10%
• Cyclosporine 10%
• Prognostic Factor 10%
• Tacrolimus 10%
• Antimetabolite 10%
• Rapamycin 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Posttransplant Lymphoproliferative Disease 100%
• Mycophenolic Acid 30%
• Azathioprine 20%
• Receptor 10%
• Medical History 10%
• Nonhodgkin Lymphoma 10%
• Rapamycin 10%
• Ciclosporin 10%
• Tacrolimus 10%
• Antimetabolite 10%